Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland

Journal of Medical Genetics

Volumn 37, Issue 3, 2000, Pages 182-185

  McIlroy, S P ^a   Crawford, V L S ^a   Dynan, K B ^a   McGleenon, B M ^a   Vahidassr, M D ^a   Lawson, J T ^b   Passmore, A P ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; APOE; BCHE K

Indexed keywords

APOLIPOPROTEIN E4; CHOLINESTERASE; ENZYME VARIANT;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UNITED KINGDOM;

EID: 0034096612     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.37.3.182     Document Type: Article

References (30)

1. Smith MA. Alzheimer disease. Int Rev Neurobiol 1998;42:1-54.
2. Khachaturian Z. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-105.
3. Tanzi RE, Gaston S, Bush A, et al. Genetic heterogeneity of gene defects responsible for familial Alzheimer's disease. Genetics 1994;91:255-63.
4. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA 1995;92:4725-7.
5. Lehmann DJ, Johnsin C, Smith AD. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet 1997;6:1933-6.
6. Guillozer AL, Smiley JF, Mash DC, Mesulam MM. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997;42:909-18.
7. Perry EK. The cholinergenic system in old age and Alzheimer's disease. Age Ageing 1980;9:1-8.
8. Barber K, Mesulam M, Kraft G, Klein W. Butyrylcholinesterase (BchE) alters the aggregation state of Aβ amyloid. Soc Neurosci Abstr 1996;22:1172.
9. Bartels CF, Jensen FS, Lockridge O, et al. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet 1992;50:1086-103.
10. Sandbrink R, Gasperina A, Zerfass R, et al. Butyrylcholinesterase K variant (BCHE K): association with late-onset Alzheimer's disease. Neurobiol Aging 1998;19:S69A.
11. Wiebusch H, Poirier J, Sévigny P, Schappert K. Further evidence for a synergistic association between APOE ε4 and BCHE-K in confirmed Alzheimer's disease. Hum Genet 1999;104:158-63.
12. Brindle N, Song Y, Rogaeva E, et al. Analysis of the butyryl-cholinesterase gene and nearby chromosome 3 markers in Alzheimer's disease. Hum Mol Genet 1998;7:933-5.
13. Crawford F, Fallin D, Suo A, et al. The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic- and community-based populations. Neurosci Lett 1998;249:115-18.
14. Helbeque N, Cottel D, Hermant X, Guez D, Amouyel P. The butyrylcholinesterase K variant is not associated with Alzheimer's disease. Alz Rep 1998;1:309-13.
15. Hiltunen M, Mannermaa A, Helisalmi S, et al. Butyrylcholinesterase K variant and apolipoprotein E4 genes do not act in synergy in Finnish late-onset Alzheimer's disease patients. Neurosci Lett 1998;250:68-71.
16. Kehoe PG, Williams H, Holmans P, et al. The butyrylcholinesterase K variant and susceptibility to Alzheimer's disease. J Med Genet 1998;35:1034-5.
17. Evans RT, Wardell J. On the identification and frequency of the J and K cholinesterase phenotypes in a Caucasian population. J Med Genet 1984;21:99-102.
18. Whittaker M, Britten JJ. Plasma cholinesterase variants. Family studies of the E1k gene. Hum Hered 1985;35:364-8.
19. Hosseini J, Firuzian F, Feely J. Ethnic differences in the frequency distribution of serum cholinesterase activity. Ir J Med Sci 1997;166:10-20.
20. Zchocke J, Mallory JP, Eiken HG, Nevin NC. Phenylketonuria and the peoples of Northern Ireland. Hum Genet 1997;100:189-94.
21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services task force of Alzheimer's disease. Neurology 1984;34:939-44.
22. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
23. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;13:1215.
24. Jensen FS, Nielsen LR, Schwartz M. Detection of the plasma cholinesterase K variant by PCR using an amplification-created restriction site. Hum Hered 1996;46: 26-31.
25. Crooks R, Hardy J, Duff K. Single-day apolipoprotein E genotyping. J Neurosci Methods 1994;53:125-7.
26. McIlroy SP, Dynan KB, McGleenon BM, Lawson JT, Passmore AP. Cathepsin D gene exon 2 polymorphism and sporadic Alzheimer's disease. Neurosci Lett 1999;273:140-1.
27. McIlroy SP, Vahidassr MD, Savage DA, Patterson CC, Lawson JT, Passmore AP. Risk of Alzheimer's disease is associated with a very low density lipoprotein receptor genotype in Northern Ireland. Am J Med Genet 1999;88: 140-4.
28. Duara R, Barker WW, Lopez-Alberola R, et al. Alzheimer's disease: interaction of apolipoprotein E genotype, family history of dementia, gender, education, ethnicity and age of onset. Neurology 1996;46:1575-9.
29. Blacker D, Haines JL, Rodes L, et al. APOE-4 and age of onset of Alzheimer's disease: the NIMH genetics initiative. Neurology 1997;48:139-47.
30. Scacchi R, De Bernardini L, Mantuano E, Donini LM, Vilardo T, Corbo RM. Apolipoprotein E (APOE) allele frequencies in late onset sporadic Alzheimer's disease (AD), mixed dementia and vascular dementia: lack of association of epsilon 4 allele with AD in Italian octogenarian patients. Neurosci Lett 1995;210:231-4.